Ipilimumab, a monoclonal antibody that upregulates immune responses by targeting CTLA-4 (cytotoxic T-lymphocyte-associated protein 4), has been shown to prolong survival times in both previously treated and untreated metastatic melanoma patients when used in combination with other therapies [38,39]. Here, CTLA4 is linked to metastatic melanoma.